Cargando…
A Phase I study of NLG919 for adult patients with recurrent advanced solid tumors
Autores principales: | Nayak, Asha, Hao, Zhonglin, Sadek, Ramses, Vahanian, Nicholas, Ramsey, W Jay, Kennedy, Eugene, Mautino, Mario, Link, Charles, Bourbo, Pamela, Dobbins, Robin, Adams, Kelly, Diamond, Allison, Marshall, Lisa, Munn, David H, Janik, John, Khleif, Samir N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292544/ http://dx.doi.org/10.1186/2051-1426-2-S3-P250 |
Ejemplares similares
-
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
por: Nayak-Kapoor, Asha, et al.
Publicado: (2018) -
Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier
por: Sun, Jing-jing, et al.
Publicado: (2017) -
Neuroligins Nlg2 and Nlg4 Affect Social Behavior in Drosophila melanogaster
por: Corthals, Kristina, et al.
Publicado: (2017) -
Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model
por: Meng, Xiangjing, et al.
Publicado: (2017) -
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
por: Metz, Richard, et al.
Publicado: (2012)